Frontiers in Molecular Biosciences · 2022 · 39 citations · 23 references
MedicineCancer BiologyOncologyImmunotherapyMolecular OncologyTumor MicroenvironmentCancer BiomarkersCancer ImmunotherapyCancer Survival AnalysisImmuno-oncology BiomarkersMolecular Tumor ProfilingTumor ImmunopathologyBiological PrognosisHepatic Copper MetabolismImmune Infiltration Prognostic SignaturesPrognostic Biomarker DiscoveryPrognostic Expression SignaturesTumor Immune Cell InfiltrationTumor Microenvironment BiomarkersUnsupervised Clustering
Background: Copper metabolism plays an important role in the tumor microenvironment, and cuproptosis is the last discovered programmed cell death process. However, the potential mechanism of cuproptosis in regulating the immune microenvironment of HCC remains unclear. Methods: A total of 716 HCC patients with complete mRNA expression and survival information were collected from three public HCC cohorts (TCGA-LIHC cohort, n = 370; GSE76427 cohort, n = 115; ICGC-LIRI cohort, n = 231). The unsupervised clustering analysis (NMF) was performed to identify three different cuproptosis-related subtypes. The univariate-Cox, lasso-Cox and multivariate-Cox regression analyses were performed to screen the cuproptosis related and construct the cuproptosis-related prognosis signature (Cu-PS). The immune cell infiltration was estimated by both CIBERSORT and MCPcounter algorithms. Results: This study identified three distinct cuproptosis-related metabolic patterns, which presented different pathway enrichment and immune cell infiltration. The Cu-PS, a 5-genes (C7, MAGEA6, HK2, CYP26B1 and EPO) signature, was significantly associated with TNM stage, tumor mutational burden (TMB), drugs sensitivity, and immunotherapies response. Conclusion: This study performed a multi-genetic analysis of cuproptosis-related genes and further explored the regulatory mechanism of cuproptosis in HCC. The Cu-PS might be a useful biomarker for predicting immunotherapy response and enhancing the diagnosis and treatment of HCC.
23
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang, Shengqing Gu, Deng Pan et al. · Nature Medicine · 2018 · 5.6K citations · Full text
Life Sciences, Immunology, Oncology +14
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles et al. · Nature · 2018 · 5.5K citations
Life Sciences, Immunology, Oncology +16